Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Biomark Med. 2015;9(9):851-62. doi: 10.2217/bmm.15.56. Epub 2015 Sep 2.

Translating predictive biomarkers within oncology clinical development programs.

Author information

1
Departments of Oncology & Biostatistics, Bioinformatics & Biomathematics, Lombardi Comprehensive Cancer Center & Innovation Center for Biomedical Informatics, Georgetown University Medical Center, 4000 Reservoir Road NW, Suite 120 Washington, DC 20007, USA.
2
Biostatistics & Research Decision Sciences, Merck Research Laboratories, Rahway, NJ, USA.

Abstract

Predictive biomarkers provide essential information to enable personalized medicine, and hold the promise for enhancing the effectiveness and value of cancer therapies. However, they do not always work. This review provides a framework for managing the risk of predictive biomarkers and maximally harvesting their benefit. Methods are provided which permit data-driven, adaptive decision making about the use of predictive biomarkers during clinical development, applying them to the extent they are validated by the clinical data. Techniques for optimizing overall development efficiency, measured as the number of successful drug indications approved per patient utilized, are also presented.

KEYWORDS:

benefit–cost ratio; decision analysis; optimization; predictive biomarker

PMID:
26330133
DOI:
10.2217/bmm.15.56
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center